Inducible RNAi Rat Models for Reversible Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene targeting and genome editing technologies, such as CRISPR/Cas9, allow for permanent gene knockout alleles but do not enable temporal gene regulation, which is crucial for exploring therapeutic efficacy and toxicity of new drug targets effectively.
Innovation Solution
Development of inducible and conditional CRISPR/Cas9 and RNAi systems that enable reversible gene silencing in rat models, allowing for the creation of founder knock-in strains with specific nucleotide sequences and miRNA backbones for variable shRNA insertion, facilitating the simulation of new therapeutic regimes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If permanent gene knockout alleles are used, then gene editing efficiency is improved, but temporal gene regulation capability deteriorates
Solution Approach 1:
The patent applies dynamics by making the gene silencing system reversible and inducible. The RNAi system allows gene expression to be dynamically controlled - silenced when needed and restored when not needed, unlike permanent knockouts. This is achieved through inducible promoters that respond to external signals, enabling the system to adapt its state based on experimental requirements.
Solution Approach 2:
The patent changes the parameter of gene expression from permanent (knockout) to temporary and inducible (RNAi). By using RNA interference mechanisms with inducible promoters, the system transforms the static gene knockout state into a dynamic state where gene expression levels can be modulated in response to external inducers, thus achieving temporal regulation.
2Adaptability or versatility
If RNAi systems are developed for temporal gene regulation, then adaptability is improved, but device complexity increases
Solution Approach 1:
The patent achieves universality by creating a platform system that can be applied to multiple genes and multiple experimental contexts. The inducible RNAi system serves multiple functions: it can silence different genes by changing the RNAi trigger sequence, it can be induced at different time points, and it works across different tissue types. This multi-functionality reduces the need for separate systems for each application.
Solution Approach 2:
The patent uses an intermediary inducible promoter system that mediates between the external inducer signal and the gene silencing mechanism. This intermediary layer (the promoter) translates external chemical or physical signals into controlled RNAi activation, providing a buffer that simplifies the overall control architecture while enabling temporal regulation.
3Reliability
If inducible RNAi systems are implemented, then therapeutic simulation accuracy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing the inducible RNAi system in transgenic organisms during model creation. The inducible promoter and RNAi machinery are installed in advance, so that when the actual experiment is performed, only the specific RNAi trigger sequence needs to be introduced to activate gene silencing. This preliminary setup simplifies subsequent experimental procedures.
Solution Approach 2:
The patent segments the gene silencing system into modular components: an inducible promoter element, an RNAi trigger sequence, and a reporter gene. This segmentation allows each component to be independently optimized and combined, making the system easier to manufacture and adapt for different therapeutic targets while maintaining high simulation accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach transforms the preclinical validation process by enabling in vivo assessment of drug response and resistance mechanisms, guiding the development of safer and more effective drugs by mimicking the dynamics of small molecule inhibition better than permanent genetic knockouts.
Implementation Method 1
The advent of CRISPR/Cas9 genome editing, together with major advances in RNA interference technologies enables one to genetically engineer and study human diseases in mice
Implementation Method 2
RNA interference, post-transcriptional gene silencing, quelling—these different names describe similar effects that result from the overexpression of transgenes encoding double-stranded RNA precursors, or from the deliberate introduction of double-stranded RNA into cells
Data Source
AI summary
Provided herein are systems and methods for Inducible and conditional CRISPR/Cas9 and RNAi. From animal model creation and the efficiency of CRISPR-based targeting, the present invention comprises developing RNAi models that enable inducible and reversible gene silencing to simulate new therapeutic regimes.